

References

I-157

1. SPINRAZA™ (Nusinersen) injection, for intrathecal use [package insert]. Cambridge, MA: Biogen Inc. Revised 06/2020.
2. Mercuri E, Darras BT, Chriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. *N Engl J Med*. 2018;378:625-35.
3. Clinical Pharmacology Compendium®. 2022. Tampa FL: Gold Standard, Inc. Nusinersen.
4. De Vivo DC, Topaloglu H, Swoboda K et al. Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy (SMA): Interim efficacy and safety results from the phase 2 NURTURE study. 2019; 92(15).
5. Micromedex DrugDex Compendium®. 2022.
6. Zolgensma® (onasemnogene abeparvovec-xioi) injection, for intravenous use [package insert]. AveXis, Inc. Bannockburn, IL. Revised 10/2021.
7. Hayes, Inc. Hayes Prognosis Overview. Zolgensma (Onasemnogene Abeparvovec) for Spinal Muscular Atrophy. Landsdale, PA: Hayes, Inc.; February 2019.
8. Mendell J, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. *N Engl J Med*. 2017;377:1713-1722.
9. Al-Zaidy S, Pickard A, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. *Pediatr Pulmonol*. 2019;54(2):179-185.
10. Al-Zaidy S, Kolb SJ, Lowes L, et al. AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. *J Neuromuscul Dis*. 2019a;6(3):307-317.
11. Al-Zaidy S, Mendell JR. From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1. *Pediatr Neurol*. 2019;100:3-11.
12. Dabbous O, Maru B, Jansen JP, et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. *Adv Ther*. 2019;36(5):1164-1176.
13. Lowes LP, Alfano LN, Arnold WD, et al. Impact of age and motor function in a phase 1/2a study of infants with SMA type 1 receiving single-dose gene replacement therapy. *Pediatr Neurol*. 2019;98:39-45.

14. Micromedex DrugDex Compendium[®]. 2022. Onasemnogene abeparvovec.
15. Clinical Pharmacology[™] 2022. Tampa FL: Gold Standard, Inc. Onasemnogene abeparvovec.
16. Glascok J, Sampson J, Connolly A, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. *J Neuromuscul Dis*. 2020;7(2):97-100.
17. Kirschner J, Butoianu N, Goemans N, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. *Eur J Paediatr Neurol*. 2020;28:38-43.
18. Mendell J, Al-Zaidy S, Shell R, et al. Five-year extension results of the phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. *JAMA Neurol*. 2021;78(7):834-841.
19. Day J, Finkel R, Chiriboga C, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STRIVE): An open-label, single-arm, multicentre, phase 3 trial. *Lancet Neurol*. 2021;20:284-293
20. Nusinersen Sodium In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Revised January 29, 2018.